dc.contributor.author | Farajzadeh, R | |
dc.contributor.author | Zarghami, N | |
dc.contributor.author | Serati-Nouri, H | |
dc.contributor.author | Momeni-Javid, Z | |
dc.contributor.author | Farajzadeh, T | |
dc.contributor.author | Jalilzadeh-Tabrizi, S | |
dc.contributor.author | Sadeghi-Soureh, S | |
dc.contributor.author | Naseri, N | |
dc.contributor.author | Pilehvar-Soltanahmadi, Y | |
dc.date.accessioned | 2018-08-26T09:00:24Z | |
dc.date.available | 2018-08-26T09:00:24Z | |
dc.date.issued | 2017 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54906 | |
dc.description.abstract | The aim of this study was to evaluate the efficiency of using a natural substance, curcumin, encapsulated in CD44-targeting hyaluronate-polylactide (HA-PLA) nanoparticles (NPs) for the modulation of macrophage polarity from the pro-inflammatory M1 to anti-inflammatory M2 phenotype. For this purpose, the characterization of the NPs was monitored using 1HNMR, FTIR, DLS and FE-SEM. The effects of curcumin-encapsulated HA-PLA NPs on the viability of LPS/IFN-? stimulated peritoneal macrophages were determined using MTT assay. The cellular uptake of free curcumin and nano-formulated curcumin was assessed using confocal microscopy. Also, the expression levels of iNOS-2 (M1 marker), Arg-1 (M2 marker) and also pro-inflammatory cytokines were measured by real-time PCR. Data showed that the nano-formulated curcumin with spherical shape, an average diameter of 102.5?nm and high cellular uptake was significantly less toxic to peritoneal macrophages. Furthermore, the nano-formulated curcumin effectively indicated a reduction in iNOS-2 and an increase in Arg-1 levels than free curcumin. The change in macrophage phenotype by curcumin-encapsulated HA-PLA NPs could suppress the inflammation in LPS/IFN-? stimulated macrophages as evidenced by a major reduction in pro-inflammatory cytokines. Conclusively, the results suggested that the curcumin formulation with CD44-targeting HA-PLA NPs might be a promising platform for the treatment of inflammatory diseases. é 2017 Informa UK Limited, trading as Taylor & Francis Group | |
dc.language.iso | English | |
dc.relation.ispartof | Artificial Cells, Nanomedicine and Biotechnology | |
dc.subject | Diseases | |
dc.subject | Macrophages | |
dc.subject | Nanoparticles | |
dc.subject | Organic acids | |
dc.subject | Pathology | |
dc.subject | Polyesters | |
dc.subject | Polymerase chain reaction | |
dc.subject | Tissue | |
dc.subject | Anti-inflammatories | |
dc.subject | Curcumin | |
dc.subject | inflammation | |
dc.subject | Inflammatory disease | |
dc.subject | Macrophage phenotypes | |
dc.subject | Nanoparticle (NPs) | |
dc.subject | Peritoneal macrophage | |
dc.subject | Pro-inflammatory cytokines | |
dc.subject | Hyaluronic acid | |
dc.title | Macrophage repolarization using CD44-targeting hyaluronic acid-polylactide nanoparticles containing curcumin | |
dc.type | Article | |
dc.citation.spage | 1 | |
dc.citation.epage | 9 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1080/21691401.2017.1408116 | |